Kornimate/medical-research-clean huggingface dataset:
efficacy test on skin hydration and skin barrier function

Conditions: Dry Skin

Summary: the effects of topically applied pyridoxine tri-isopalmitate (p-ip) which stimulates filaggrin synthesis in keratinocytes, on skin hydration and barrier function were examined. subjects were separated into two groups to examine the effect of p-ip. subjects were treated with p-ip formulation on one side of the face and with a placebo formulation on the other side twice daily (morning and evening) for 28 days. all subjects gave written informed consent prior to the study. the skin hydration and tewl (transepidermal water loss) were evaluated by measuring skin surface conductance with a skin hygrometer skicon 200ex (i.b.s. ltd., japan) and tewl meter as-ct1 (asahi biomed, tokyo, japan), respectively.

it is expected that the long-term application of p-ip increase skin surface water contents and suppress tewl.

Eligibility criteria:
inclusion criteria: * healthy skin exclusion criteria: * don't use any moisturizer

Keywords: dry skin condition
elderly patients with renal insufficiency: reasons for using the geriatrician, modalities and results of the geriatric evaluation, becoming at one year

Conditions: Secondary Evaluation Criteria; Comorbidities and Coexisting Conditions; Motility Disorder

Summary: the incidence and prevalence of kidney failure increases with age. elderly people with chronic kidney disease may have factors of fragility (loss of independence, comorbidities, geriatric syndromes) that can complicate the choice and implementation of the nephrological therapeutic project. joint and early assessment of these patients by a nephrologist and a geriatrician could help to optimize the definition of care objectives and patient pathway. there is little data on how nephrologists and geriatricians cooperate and on the description of frailties in elderly patients with renal impairment. in this context, the objective of this study is to describe in a french university hospital the reasons for the use of geriatricians by nephrologists, the modalities of geriatric evaluation and the socio-demographic and medical characteristics (including geriatric syndromes) of very elderly patients with renal insufficiency, and then to become so at one year. year of implementation of this research: 2019 based on data from 2017 and 2019. approximate number of people likely to be included in the research: 100 patients

there is little data on how nephrologists and geriatricians cooperate and on the description of frailties in elderly patients with renal impairment. in this context, the objective of this study is to describe in a french university hospital the reasons for the use of geriatricians by nephrologists, the modalities of geriatric evaluation and the socio-demographic and medical characteristics (including geriatric syndromes) of very elderly patients with renal insufficiency, and then to become so at one year. secondary objectives : * describe the modalities of the geriatric evaluation * describe the socio-demographic, medical characteristics (including fragilities and/or geriatric syndromes) of elderly patients with renal insufficiency * describe how to become one year old. origin and nature of the data collected: - socio-demographic, medical and geriatric data (see attached document) based on geriatric assessment medical records (reports of external geriatric consultation and/or intervention by the mobile geriatric team). the approximate duration of the study will be 9 months. this time includes the time required for statistical analysis and writing an article.

Eligibility criteria:
inclusion criteria: * 75-year-old patient and older * renal insufficiency * use in 2017 and 2018 of a geriatric evaluation at the nîmes university hospital at the request of nephrologists (mobile geriatric team or external geriatric consultation). exclusion criteria: * patient under guardianship, curatorship or judicial protection * patient under 75-year-old
the combination of atra and high-dose dexamethasone as first-line treatment in adult immune thrombocytopenia

Conditions: Immune Thrombocytopenia

Summary: randomized, open-label, multicenter study to compare the efficacy and safety of atra plus high-dose dexamethasone compared to high-dose dexamethasone monotherapy for the first-line treatment of adults with primary immune thrombocytopenia (itp).

the investigators are undertaking a parallel group, multicenter, randomized controlled trial of 132 adults with itp in china. patients were randomized to atra+ high-dose dexamethasone and high-dose dexamethasone monotherapy group. platelet count, bleeding and other symptoms were evaluated before and after treatment. adverse events are also recorded throughout the study.

Eligibility criteria:
inclusion criteria: 1. confirmed newly-diagnosed, treatment-naive itp; 2. platelet counts \<30×109/l ; 3. platelet counts \< 50×109/l and significant bleeding symptoms (who bleeding scale 2 or above); 4. willing and able to sign written informed consent. exclusion criteria: 1. received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 6 months before the screening visit; 2. received first-line and second-line itp-specific treatments (eg, steriods, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) ; 3. current hiv infection or hepatitis b virus or hepatitis c virus infections; 4. active infection; 5. maligancy; 6. severe medical condition (lung, hepatic or renal disorder) other than chronic itp. unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia); 7. female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period; a history of clinically significant adverse reactions to previous corticosteroid therapy 8. have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct coombs test; 9. patients who are deemed unsuitable for the study by the investigator.
urinary vegf levels in gbm patients on radiation treatment protocol

Conditions: Glioblastoma

Summary: study of the urinary vascular endothelial growth factor (vegf) levels in patients with glioblastoma, receiving standard therapy. hypothesis: that urinary vegf levels can serve as a predictor of treatment response and survival.

measurement of urinary vegf levels pre treatment,immediately after treatment, and 1 month after treatment

Eligibility criteria:
inclusion criteria: * patient must be enrolled on an rtog gbm study that prescribes 6000 cgy of radiation therapy. * patient must meet the eligibility requirements for the rtog treatment study. (if the patient is deemed retrospectively ineligible for the rtog treatment study, the patient will likewise be ineligible for this study.) * patient must sign a study-specific informed consent for rtog 0611 prior to study entry. exclusion criteria: * patient not able to receive 6000 cgy of radiation therapy.

Keywords: gbm glioblastoma urine vegf radiation patients must be enrolled to an rtog gbm study that prescribes 6000 cgy of radiation therapy.
efficacy of nanoparticle-incorporated bonding agent on post-restorative sensitivity

Conditions: Carious Lesion

Summary: type of study: randomized clinical trial to compare post-restorative sensitivity between titania nanoparticle reinforced bonding agent and bonding agent without nanoparticles in posterior composite restorations. participants aged 18 years and above with class-i and class-ii carious lesions are allocated in two groups. group a will undergo composite restoration with nanoparticles incorporated in bonding agent. group b will undergo restoration without nanoparticles in bonding agent.

in this study novel titania nanoparticle reinforced bonding agent will be evaluated for post-restorative sensitivity in composite restorations. participants following the inclusion criteria will be allocated in this study by consecutive non-random sampling technique. participants will be divided into two groups a and b. after rubber dam isolation, carious lesion will be excavated. in group a, titania nanoparticle reinforced bonding agent will be used for restorative treatment while in group b, bonding agent without nanoparticles will be used. post-restorative sensitivity record will be taken at 24 hours, after one week and after one month. sensitivity will be assessed using visual analog scale (vas) mean score.

Eligibility criteria:
inclusion criteria: * participants with good general health * selected teeth should be vital and periodontally healthy * class-i and ii with minimal cavity depth of 3mm, not exceeding 5mm * defective previous restorations in need of replacement (secondary caries/fractures) * selected teeth should be in occlusion with natural or prosthetic antagonist and adjacent teeth exclusion criteria: * patients with temporomandibular disorders * extremely poor oral hygiene status * teeth with very deep carious lesions * teeth with periapical or periodontal pathology * patients taking anti-inflammatory, analgesics or psychotropic drugs * history of spontaneous pain * previously root canal treated teeth

Keywords: composite resins dentin bonding agents dentin sensitivity nanoparticles titania
treatment with atomoxetine hydrochloride in children and adolescents with adhd

Conditions: Attention-Deficit/Hyperactivity Disorder; Comorbid Dyslexia

Summary: the purpose of this study is to assess the efficacy and safety of atomoxetine administered once daily in the treatment of children and adolescents with adhd and comorbid dyslexia.


Eligibility criteria:
inclusion criteria: * patients with adhd only or adhd and dyslexia * at least 10 years old and no more than 16 years old * iq score of 80 or more * must be able to swallow capsules exclusion criteria: * have received treatment within last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry * weigh less than 25 kg or greater than 70 kg * pregnant or breast feeding * documented history of bipolar i or ii disorder, or psychosis * documented history of autism, asperger's syndrome or pervasive developmental disorder
the influence cirrhosis of the liver on the coronary re-stenosis (ltx- stent study)

Conditions: Re-stenosis; Cirrhosis of the Liver

Summary: the aim of the study is to choose an optimal stent and to get further knowledge about the mechanisms of the engraftment of a stent. the occurrence of a hyperplasia of neointima can be minimized by application of a coated stent and a concurrent safety four weekly dual thrombocytes therapy


Eligibility criteria:
inclusion criteria: * male and female patients with a severe dysfunction of liver * patient is planned a coronary stent implantation * adults who are contractually capable and mentally able to understand and follow the instructions of the study personnel * written informed consent prior to study participation exclusion criteria: * younger than 18 years * pregnancy and breast-feeding * acute cardiac syndrome * contraindication against an intracardiac catheter * persons in dependence from the sponsor or working with the sponsor * participation in a parallel interventional clinical trial * patient has been committed to an institution by legal or regulatory order

Keywords: ltx study
the prospecive observational munich interventional mitral-valve registry

Conditions: Mitral Valve Regurgitation; Mitral Valve Stenosis; Tricuspid Valve Regurgitation

Summary: prospective, single-center observational registry including all consecutive patients treated with transcatheter mitral or tricuspid valve therapy at the deutsches herzzentrum münchen, germany.

long-term mortality after transcatheter mitral or tricuspid valve therapy

Eligibility criteria:
inclusion criteria: * age above 18 years and consentable * mitral valve regurgitation, mitral valve stenosis, tricuspid valve regurgitation, tricuspid stenosis * transcatheter mitral or tricuspid valve therapy considered best option by heart-team decision * written informed consent exclusion criteria: * patient's inability to fully cooperate with the protocol
effects of sensory integration training on balance and confidence in patients with parkinson's disease

Conditions: Parkinson Disease

Summary: the objective of this research was to study the effectiveness of sensory integration training on balance and confidence in patients with parkinson's disease. null hypothesis: sensory integration training and conventional balance training have no significant difference in improving balance and confidence of patients with parkinson's disease. alternative hypothesis: sensory integration training and conventional balance training have a significant difference in improving balance and confidence in patients with parkinson's disease.

the study design will be randomized controlled clinical trial. patients who fulfill the inclusion criteria will be identified by individual physiotherapist and will be enrolled for particular study. a sample size of 46 patients will be taken in this study by expecting a mean change 10.42 using 80% power of study and 95% level of significance and 20% dropout will also be included. so each group contains 23 participants. the study will be single blinded. the outcome assessor will be unaware of the treatment given to both groups. sample will be collected through simple random sampling technique, and randomization sequencing will be generated with help of lottery. after selection the sample patients will be divided into two groups, allocation concealment will be ensured by using sealed envelopes. group a will be given conventional balance training along with routine physical therapy without sensory integration and group b will be given sensory integration physical therapy along with routine physical therapy. group a will be called control group and group b will be called experimental group. every patient has to pick up an envelope which will be placed in patient's file which later will be opened by the researcher who will provide patient treatment accordingly.

Eligibility criteria:
inclusion criteria: * male and female patients diagnosed by a neurologist with parkinson's disease. * patients having bbs score between 21-40 * at least 6 months post neurological sensory/motor deficit patient. * age between 30 -65 years. * ability to maintain standing position without aids for at least 5 minutes. * normal vision * no severe systemic disorders * an ability to understand and perform the test exclusion criteria: * patients with other existing neuromuscular disorders or medical conditions that substantially influences their gait and balance performance * neuropathy patients * vestibular disorders, paroxysmal vertigo. * presence of orthopedic conditions involving the lower limbs. * patients with psychiatric disorders. * pregnant patients.

Keywords: parkinson disease sensory integration training berg balance scale balance activities-specific balance confidence scale
superiority of omega-3 versus placebo on the improvement of adhd in children

Conditions: Attention Deficit Hyperactivity Disorder (ADHD)

Summary: this study aims to evaluate the efficacy of an omega-3 fatty acid supplement on improving the attention deficit hyperactivity disorder (adhd) clinical symptoms.

this is a multicenter, controlled, randomized, prospective, parallel-group, double-blind study to evaluate the effect of an omega-3 fatty acid supplement with epa, dha, vitamins e and d on adhd clinical symptoms (according to diagnostic and statistical manual for mental disorders, 4th. edition (dsm-iv-tr) criteria) in children between 6 and 11 years. patients will be randomized to receive either the new omega-3 supplement or a placebo during 6 months.

Eligibility criteria:
inclusion criteria: * age between 6 and 11 years 11 months. * adhd diagnosis according to dsm-iv-tr criteria * children whose parents are able to reliably meet all visits and all the tests required for this study based on the researcher judgment * patient representative (either parents or legal guardians) must understand the conditions of the study and sign the informed consent exclusion criteria: * patients who do not meet diagnostic criteria for adhd * patients with a previously known allergy or intolerance to the components of omega- 3 supplement * patients with underlying diseases that, according to medical criteria , are not eligible for supplementation with omega-3 fatty acids : fatty liver disease (or other liver disease), bleeding disorders and cardiovascular disease * patients with allergies to fish and /or shellfish * patients who have received adhd pharmacological treatment or fatty acid supplements at any dose for more than 7 consecutive days within the last 3 months * patients who have received psychological or psycho-educational treatment in the past 3 months * patients who have had some kind of psychometric diagnostic tests in the last year * patients with scores corresponding to a lower mental age (more than 1 year less) according to the wechsler intelligence cubes scale for children (wisc-iv) * patients with severe emotional problems according to the cas or staic tests * patients participating in another clinical trial

Keywords: omega-3 adhd quality of life inattention hyperactivity
infrared thermography associated with cutaneous microcirculation for detection of brown-adipose tissue (microbat)

Conditions: Pheochromocytoma; Paraganglioma

Summary: patients affected by pheochromocytoma (pheo) have brown-adipose tissue (bat) hyperactivation. they perform, in routine settings, a fdg pet-ct scan. the high metabolic activity of bat and its ability to consume both glucose and fatty acid suggest that it may have potential as a therapeutic target in the treatment of obesity. however, alternative non-invasive techniques to pet-ct bat detection still need more validation. accordingly, our aim will be to measure the temperature and microcirculation of the skin overlaying bat depots in the region of fdg-uptake detected by 18f-fdg pet/ct before and after a cold test in pheo patients.

objectives and methodology: * to analyse the change in temperature and microcirculation of the skin overlaying bat depots in the region of fdg-uptake detected by 18f-fdg pet/ct before and after a cold test in pheo patients. * to check the decreased temperature and microcirculatory response after a cold test following resection of the tumor all the patients affected by will benefit from a: * clinical: treatments * biological evaluations: glycemia, triglycerides, total cholesterol, hdl-c, ldl-c, plasma epinephrine and norepinephrine, urine catecholamine * cutaneous microcirculation by means of laser speckle imaging will be recorded at rest and during a cold test in the supra-clavicular region * cutaneous microcirculation by means of laser doppler flowmetry will be recorded at rest and during a cold test with one probe in the supra-clavicular region and one probe in umbilical region * skin temperature by means of infrared thermography will be recorded at rest and during a cold test in the supra-clavicular region patients who will have surgery will be investigated before and after one year following resection of the tumor.

Eligibility criteria:
inclusion criteria: * patients with confirmed pheochromocytoma and/or paraganglioma exclusion criteria: * pregnant woman * breastfeeding woman

Keywords: pheochomocytoma brown adipose tissue infrared thermography cutaneous microcirculation pet-ct
comorbidity screening and referral by prosthetists

Conditions: Limb Ischemia; Low Back Pain; Depression; Neuropathy;Peripheral; Amputation

Summary: lower-limb amputation is associated with life-altering and life-limiting comorbidities. currently, onus is on primary care providers to diagnose, educate, and refer patients for appropriate management. recently our laboratory has found, however, that of adults post-amputation seen in an outpatient limb loss clinic presenting with comorbidities, \>50% are unaware they have signs of peripheral arterial disease and/or neuropathy. lack of patient awareness and thus, inadequate comorbidity management, may contribute to suboptimal patient outcomes post-amputation. as a first step in this research line, the proposed project will help determine if comorbidity screening by prosthetists during routine care visits for patients post-amputation may enhance comorbidity awareness, increase patient satisfaction in prosthetic services, and reduce gratuitous prosthetic service utilization. during a follow-up visit, seventy patients following a unilateral lower-limb amputation will be randomized into either a standard-of-care group or a standard of-care plus group. the standard-of-care plus group will receive clinical screenings by a certified prosthetist for peripheral arterial disease, peripheral neuropathy, depression, and high-risk for persistent back pain; patient education on findings; and each participant's primary care provider will receive screening results. the long-term goal of this research is to determine if prosthetists can maximize their utility in an interdisciplinary care team, while enhancing patient outcomes post-amputation.


Eligibility criteria:
inclusion criteria: * english-speaking and -reading * unilateral transtibial (i.e., below-knee) or transfemoral (i.e., above-knee) amputation * utilization of a prosthesis for at least 1 year * willingness to have screening results communicated to their primary care provider * receiving prosthetic care at independence prosthetics-orthotics, inc. exclusion criteria: * cognitive impairment precluding ability to consent to study participation * contralateral limb amputation greater than toe-level * severe vision or hearing loss * receipt of a replacement prosthetic component within the 3 months prior to study enrollment * hospitalization within the 3 months prior to study enrollment

Keywords: comorbidity peripheral arterial disease sensation back pain mental health amputation
alcohol consumption and gallbladder cancer

Conditions: Gallbladder Cancer

Summary: this case-control study matched by age and sex was performed to evaluate the region specific risk factors for gallbladder cancer in jeju island, korea.

in order to estimate region-specific risk factors for gallbladder cancer (gbc) in jeju island, korea the investigators performed a case-control study. among 124 gbc patients and 7088 health controls, the investigators randomly selected 78 cases and 78 age-sex matched controls (1:1 matching) and compared their demographic features, combined diseases, and personal histories about known risk factors until now.

Eligibility criteria:
inclusion criteria: * case group : newly diagnosed gallbladder cancer patients in digestive disease center, department of internal medicine in cheju halla general hospitalduring 2008-2013 * control group : 1:1 age-sex matched controls underwent health care screening program in department of health promotion center in cheju halla general hospital for 2008-2012. exclusion criteria: * case group ambiguous diagnosis primary tumor involving common bile duct follow up loss without pathologic confirmation incomplete clinical records couldn't be assessed the results of operation or radiologic imaging. * control group cases unavailable for gallbladder imaging (abdominal ultrasonography ,computed tomography, or magnetic resonance imaging) cases underwent previous cholecystectomy before enrollment.

Keywords: gallbladder cancer case-control study risk factor alcohol consumption polypoid lesions of gallbladder biliary stone